| INTRODUC TI ON
Accurate measurement of factor VIII (FVIII) activity is important for guiding treatment decisions.
1,2 FVIII activity is typically measured using the one-stage and, in some cases, the chromogenic assays. 3 Although the one-stage assay is used in most laboratories worldwide for postinfusion monitoring, results are highly variable and may be influenced by reagents and different laboratory practices. 3, 4 Because discrepancies in the measurement of modified FVIII products using the one-stage assays have been recognized, studies specifically addressing the ability of clinical laboratories to accurately measure these products have been undertaken. [5] [6] [7] BAY 94-9027 is an extended half-life (EHL) FVIII molecule. Safety and efficacy have been demonstrated in multiple studies in adults, adolescents and children using tailored regimens with dosing intervals up to every 7 days. 8, 9 BAY 94-9027 is an engineered B-domaindeleted recombinant FVIII (rFVIII) that is site-specifically conjugated to a single 60-kD polyethylene glycol (PEG) molecule (2 × 30 kDa branched) at a cysteine variant to reduce the clearance of FVIII and prolong its activity in circulation. 10, 11 Because BAY 94-9027 is a modified molecule, there is the potential for differences in performance when it is measured in coagulation assays established for standard FVIII products. Thus, this study was designed to assess the ability of clinical laboratories to accurately measure FVIII activity after BAY 94-9027 administration using their routine assays and methods.
| ME THODS

| Study design
The study consisted of 2 parts. In part 1, laboratories analysed test samples using their in-house (one-stage or chromogenic) assays, reagents and standards (calibrators), which referenced back to the World Health Organization (WHO) International Standard used by the laboratory and controls; the WHO 8th International
Standard was provided to laboratories if requested. Laboratories that had the capacity to measure samples using both the one-stage and chromogenic assays were given an additional sample set to test. Part 1 focused predominantly on testing in-house one-stage reagents because the chromogenic assay was previously shown to accurately measure BAY 94-9027 activity. 12 In part 1, information regarding assay type, instrument, reagents (activator kits, calibrators, and factor-deficient plasma) and dilutions were also collected from individual laboratories; differences in laboratory practices have been shown to affect FVIII measurements. 3, 4 To ensure that part 1 captured both the prevalence and heterogeneity of onestage assay kits used in the geographic region studied, laboratories that had ≥2 routine one-stage assays were sometimes asked to perform sample testing with one of the less commonly used kits in the laboratory. In part 2 of the study, all participating laborato- Accuracy was assessed in terms of spiked recoveries falling within the acceptance criteria (geometric mean of 80%-125% of the target value). 
| Field study assays
| Statistical analysis
All laboratories that provided data for ≥1 sample were included in the full analysis set. The comparator product and plasma controls were used to assess the ability of laboratories to measure FVIII based on their in-house assays and laboratory methods. To minimize variability resulting from general testing issues, laboratories that achieved 80% to 125% of the target value in ≥66% of the high control samples (ie, 2 of 3 or 3 of 4 tests) in part 1 were included in the valid assessments in high control (VAHC) analysis set. Statistical analyses were performed using SAS ® 9.2 software (SAS Institute Inc., Cary, NC, USA). Results were analysed for intralaboratory and interlaboratory variability. Sample statistics (mean, SD, median, quartiles, ranges)
were calculated for numeric data, and frequencies were calculated for categorical data. Because of separate endpoints, results were analysed separately for in-house reagents in part 1 and Bayer-provided reagents (Pathromtin SL and SynthASil) in part 2.
| RE SULTS
| Participating laboratories
Fifty-two laboratories from North America (n = 25), Europe (n = 26) and Israel (n = 1) participated in the study. All 52 laboratories were included in the full analysis set, and 48 laboratories qualified for the VAHC analysis set, indicating that most laboratories could accurately measure FVIII. In part 1, 36 laboratories tested samples using only the one-stage assay, 3 tested samples using only the chromogenic assay and 13 used both assays. Assay reagents, including kit and use of FVIII-deficient or depleted plasma, varied in part 1 of the study; differences in the analyzer and calibration practices were also observed in part 1 ( Table 2 ). In part 2, SynthASil and Pathromtin SL were used to test samples in 52 and 51 laboratories, respectively, which included some laboratories that used only the chromogenic assay in part 1.
| Chromogenic assay results
Geometric mean FVIII recovery ranged from 104.4% to 117.1% for BAY 94-9027, which was similar to results for rAHF-PFM (87.7%-107.8%) using the chromogenic assay ( Figure 1A ). Accurate results were obtained for all 3 chromogenic assay reagents used in part 1 ( Figure 
| One-stage assay results (overall)
Overall recoveries for both BAY 94-9027 and rAHF-PFM were also similar for most of the one-stage reagents tested in parts 1 and 2 of the study ( Figure 2A and B), and recovery was similar between the VAHC analysis set and the full analysis set (data not shown).
Intralaboratory variability was comparable between BAY 94-9027, rAHF-PFM and normal plasma in both parts 1 and 2 (Tables 3 and 4 ).
Interlaboratory variability was higher for BAY 94-9027 in part 1, but percentage CV decreased in part 2 when all participating laboratories used the Pathromtin SL and SynthASil kits, which can accurately measure BAY 94-9027 and full-length FVIII (Tables 3 and 4) .
Because the overall one-stage assay data suggested some differences between the results obtained with in-house assays (part TA B L E 1 Composition of each sample set 1) versus specific appropriate assays (part 2), the data were further analysed. Part 1 results were analysed to determine if all one-stage assays were comparable in performance, whereas part 2 results
were assessed to determine whether further improvements in assay outcomes were possible when guidance regarding appropriate onestage reagents was given.
| One-stage assay results (part 1)
In part 1, accurate results for BAY 94-9027 were obtained at all levels with the ellagic acid-based reagent Actin ® FSL (Siemens) and were within or close to range for medium and high levels with the silica-based reagents SynthASil and Pathromtin SL ( Figure 3A) ; analyzers used are listed in Table 2 . ACL (Instrumentation Laboratory) was used for SynthASil and BSC XP (Siemens, Erlangen, Germany) and CS2100i (Sysmex, Kobe, Japan) for Pathromtin SL in part 1 of the study. These results confirmed the previous findings 13, 14 that both ellagic acid-and silica-based reagents can be used to measure FVIII activity after BAY 94-9027 administration. Increased variability was seen with the kaolin-based reagent C.K. Prest ® (Stago, Asnières sur Seine, France) versus other one-stage reagents. Actin FS also overestimated activity, particularly at low concentrations ( Figure 3A ). The interlaboratory and intralaboratory variabilities with these kits were generally low for BAY 94-9027
and comparable to rAHF-PFM ( Figure 3B and C). Two silica-based reagents, PTT-A and APTT-SP, underestimated FVIII recovery (<25% and <18%, respectively; Figure 3A ) at all concentrations of BAY 94-9027, which confirmed previous in vitro study findings. 12, 14 The intralaboratory and interlaboratory variations for BAY 94-9027 obtained with these 2 kits were higher versus other one-stage kits ( Figure 3B and C). The one-stage assay interlaboratory variability for recoveries measured by laboratories with these 2 reagents was ≥75%, whereas the variability with the other one-stage reagents was generally <25% ( Figure 3B ). The results obtained from these specific reagents indicate that they likely contributed to the overall one-stage assay interlaboratory variability for BAY 94-9027 in part 1 (Table 3) and further demonstrate the importance of using appropriate one-stage assay reagents when measuring BAY 94-9027 activity.
| One-stage assay results with specified kits (part 2)
In part 2, the accuracy and variance in BAY 94-9027 assay performance was assessed when laboratories were given appropriate reagents, although no guidance was given regarding the analyzers to be used. In addition to the FVIII spiked recoveries falling within the expected range with both Pathromtin SL and SynthASil ( Figure 2B ), the interlaboratory variability was reduced for BAY 94-9027 in part 2 when using these reagents (Table 4) versus part 1 using in-house kits (Table 3) ; variability was comparable to rAHF-PFM and high control, demonstrating that laboratories were uniformly able to accurately measure FVIII activity ( were observed with test sites using the ellagic acid-based reagent Actin FSL and silica-based reagents Pathromtin SL and SynthASil in part 2 of the study, when all sites used these specific reagents.
| D ISCUSS I ON
Actin FS and the kaolin-based reagent C.K. Prest showed some overestimation of BAY 94-9027 activity, particularly at lower concentrations, versus the selected one-stage assay reagents tested.
Two specific silica-based one-stage assays, APTT-SP and PTT-A, underestimated BAY 94-9027 activity at all concentrations; this is consistent with previous findings. 12, 14 These data expand upon the existing literature on assay performance with BAY 94-9027. [12] [13] [14] Earlier studies have shown that FVIII activity measurements for BAY 94-9027 spiked into FVIII-deficient plasma were similar to the WHO 8th International Standard using both chromogenic assay and ellagic acid-based one-stage assays.
These studies also showed that specific silica-based one-stage assays underestimated BAY 94-9027 activity. 12, 14 Another earlier study showed that other commonly used silica-based one-stage assays (Pathromtin SL and SynthASil) were able to provide accurate measurements, 13 which contradicted earlier conclusions that only ellagic acid-based activators can be used to measure FVIII activity with BAY 94-9027. 12, 14 These important findings have been replicated and confirmed by this international laboratory study.
With the use of selected commonly available one-stage assay reagents, we anticipate BAY 94-9027 activity measurement to be reproducible. This is confirmed by the low interlaboratory variability in recovery measurements seen when appropriate one-stage reagents are used. Standardization of reagents and laboratory practices may further decrease variability when measuring FVIII with all products in clinical practice.
It has been shown that discrepancies and variability in results using different assays or reagents have been documented for all modified rFVIII products, including B-domain-deleted and EHL products. [5] [6] [7] [15] [16] [17] Although the methods used to modify FVIII vary among manufacturers of EHL products, 2 it is apparent that some modified proteins behave differently in some one-stage assays compared with unmodified FVIII products. 15 The variable performance As previously reported, 3 and as confirmed in this study, there is a wide range of one-stage assay reagents and laboratory practices used worldwide to measure FVIII activity. Without global standardization of assays and methods, clinicians and clinical laboratories must be informed of the specific modified FVIII product each patient has received so that the appropriate assay and reagents can be used for optimal monitoring. 2 As reported in this study and others, 7,16 the availability of assay-and reagent-specific data is vital to assist clinical laboratories in choosing the appropriate assay conditions to ensure safe and effective postinfusion monitoring. Given the number of available aPTT assays, the assays tested in field studies are by no means exhaustive, and laboratories should determine that they have suitable assays available before undertaking patient monitoring. One approach may be the one adopted by the UK Haemophilia Centres Doctors' Organisation, which recommends that laboratories use an assay that has been validated for use with the specific EHL product being measured. 
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